-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Marijuana Research Focuses Strictly On Potential Harms From THC, NCCIH Director Says
Marijuana Research Focuses Strictly On Potential Harms From THC, NCCIH Director Says
Director of the National Center for Complementary and Integrative Health (NCCIH) Helene Langevin recently pointed out that the abundance of federally funded research on cannabis has "narrowly focused on the potential harms" of THC.
"There is growing interest among health care providers and the public in understanding the potential therapeutic uses of cannabis-related products," Langevin said. "But that interest must be matched by research that can deepen our knowledge and inform health decisions."
The fact that marijuana still remains a Schedule I drug under the Controlled Substances Act (CSA) is the main barrier that's hindered studies, Langevin pointed out. "Research on cannabinoids is fraught with hurdles," she continued.
In addition, NCCIH recently published a "Request for Information" (RFI), soliciting feedback from the scientific community "about its interest in and barriers to research on the health effects of cannabis and its constituents," Marijuana Moment first reported.
What Would Be The Solution To Avoid Cannabis Research Obstacles?
"A key step in successfully generating more scientific evidence around the potential clinical uses of cannabis products is to identify barriers to conducting research and subsequently develop approaches that can help overcome them," Langevin said. "The RFI responses we receive will help broaden our understanding of the research infrastructure needed to foster rigorous studies and identify areas of interest within the field."
Langevin said she views NCCIH's "ongoing work in cannabinoids research as a natural extension of our broader effort to advance the scientific understanding of whole person health."
More Research To Stop Public Health Crisis
In addition, the National Institutes of Health (NIH) recently released a Notice of Special Interest (NOSI) to promote "mechanistic research" into minor cannabinoids like CBG, CBN, and delta-8 THC.
"These activities are timely, especially given the potential role of cannabinoids in managing pain," Langevin said. "The overreliance on opioids has created a public health crisis and incalculable losses across the nation. Driving research that could yield new, potentially safer tools that meet the needs of people who suffer from chronic pain is an essential step in addressing the problem at its root."
Recently, Khiron Life Sciences Corp. (OTCQX:KHRNF) (TSXV: KHRN.V) published in the international peer-reviewed journal Frontiers in Pain Research the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the first published clinical evidence on the effectiveness and safety of Khiron's THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron's Zerenia Clinics in Colombia.
Photo: Courtesy Of Girl with red hat On Unsplash
Director of the National Center for Complementary and Integrative Health (NCCIH) Helene Langevin recently pointed out that the abundance of federally funded research on cannabis has "narrowly focused on the potential harms" of THC.
"There is growing interest among health care providers and the public in understanding the potential therapeutic uses of cannabis-related products," Langevin said. "But that interest must be matched by research that can deepen our knowledge and inform health decisions."
國家補充與綜合健康中心的董事海琳·朗之萬 最近指出,聯邦政府資助的大量大麻研究“狹隘地集中在四氫大麻酚的潛在危害上”.
朗之萬説:“衞生保健提供者和公眾對了解大麻相關產品的潛在治療用途越來越感興趣。”但這種興趣必須與能夠加深我們的知識併為健康決策提供信息的研究相匹配。
The fact that marijuana still remains a Schedule I drug under the Controlled Substances Act (CSA) is the main barrier that's hindered studies, Langevin pointed out. "Research on cannabinoids is fraught with hurdles," she continued.
朗之萬指出,根據受控物質法案(CSA),大麻仍然是第一類藥物,這一事實是阻礙研究的主要障礙。“對大麻素的研究充滿了障礙她繼續説道。
In addition, NCCIH recently published a "Request for Information" (RFI), soliciting feedback from the scientific community "about its interest in and barriers to research on the health effects of cannabis and its constituents," Marijuana Moment first reported.
此外,NCCIH最近發表了一份“索取資料(RFI),正在徵求科學界的反饋意見,“關於他們對大麻及其成分對健康影響的研究的興趣和障礙”,大麻時刻首次報道。
What Would Be The Solution To Avoid Cannabis Research Obstacles?
什麼是避免大麻研究障礙的解決方案?
"A key step in successfully generating more scientific evidence around the potential clinical uses of cannabis products is to identify barriers to conducting research and subsequently develop approaches that can help overcome them," Langevin said. "The RFI responses we receive will help broaden our understanding of the research infrastructure needed to foster rigorous studies and identify areas of interest within the field."
要成功地圍繞大麻產品的潛在臨牀用途產生更多科學證據,關鍵的一步是找出進行研究的障礙,並隨後開發有助於克服這些障礙的方法。朗之萬説。我們收到的RFI答覆將有助於擴大我們對促進嚴格研究和確定該領域感興趣領域所需的研究基礎設施的瞭解。“
Langevin said she views NCCIH's "ongoing work in cannabinoids research as a natural extension of our broader effort to advance the scientific understanding of whole person health."
朗之萬説,她認為NCCIH的正在進行的大麻素研究工作是我們推進對整體健康的科學理解的更廣泛努力的自然延伸。“
More Research To Stop Public Health Crisis
更多研究遏制公共衞生危機
In addition, the National Institutes of Health (NIH) recently released a Notice of Special Interest (NOSI) to promote "mechanistic research" into minor cannabinoids like CBG, CBN, and delta-8 THC.
此外,美國國立衞生研究院(NIH)最近發佈了一個特別利息通知書(NOSI)推動“機械論研究”少量大麻素,如CBG、CBN和Delta-8 THC.
"These activities are timely, especially given the potential role of cannabinoids in managing pain," Langevin said. "The overreliance on opioids has created a public health crisis and incalculable losses across the nation. Driving research that could yield new, potentially safer tools that meet the needs of people who suffer from chronic pain is an essential step in addressing the problem at its root."
“這些活動是及時的,特別是考慮到大麻類藥物在止痛方面的潛在作用,”朗之萬説。對阿片類藥物的過度依賴在全國範圍內造成了公共健康危機和不可估量的損失。推動研究,可能產生新的、潛在更安全的工具,滿足慢性疼痛患者的需求,是從根本上解決問題的關鍵一步。
Recently, Khiron Life Sciences Corp. (OTCQX:KHRNF) (TSXV: KHRN.V) published in the international peer-reviewed journal Frontiers in Pain Research the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the first published clinical evidence on the effectiveness and safety of Khiron's THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron's Zerenia Clinics in Colombia.
最近, 科隆生命科學公司。(OTCQX:KHRNF)(TSXV:KHRN.V)發表在國際同行評議中疼痛研究前沿雜誌該中心首次對哥倫比亞患者使用醫用大麻治療慢性疼痛進行了臨牀研究。這是首次發表的關於Khron的THC和CBD油基大麻製劑有效性和安全性的臨牀證據,這兩種產品是Khron在哥倫比亞的Zerenia診所最常用的處方產品。
Photo: Courtesy Of Girl with red hat On Unsplash
圖片:Unspash上戴紅帽子的女孩提供
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧